About Lyra Therapeutics
Lyra Therapeutics is a company based in Watertown (United States) founded in 2005 by George Whitesides and Robert Langer. Lyra Therapeutics has raised $127.61 million across 12 funding rounds from investors including HHS, RA Capital and Perceptive Advisors. The company has 30 employees as of December 31, 2024. Lyra Therapeutics operates in a competitive market with competitors including Insulet, Decibel Therapeutics, TriSalus Life Sciences, Credence MedSystems and Akouos, among others.
- Headquarter Watertown, United States
- Employees 30 as on 31 Dec, 2024
- Founders George Whitesides, Robert Langer
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lyra Therapeutics, Inc.
-
Annual Revenue
$1.53 M (USD)-1.54as on Dec 31, 2024
-
Net Profit
-$93.44 M (USD)-49.07as on Dec 31, 2024
-
EBITDA
-$60.26 M (USD)7.64as on Dec 31, 2024
-
Total Equity Funding
$127.61 M (USD)
in 12 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Jun 09, 2023
-
Investors
HHS
& 9 more
-
Employee Count
30
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lyra Therapeutics
Lyra Therapeutics is a publicly listed company on the NASDAQ with ticker symbol LYRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Lyra Therapeutics
Lyra Therapeutics has successfully raised a total of $127.61M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lyra Therapeutics
Lyra Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, RA Capital and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked | |
|
US focused seed to growth stage VC firm
|
Locked | Locked | Locked |
Investor details for Lyra Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lyra Therapeutics
Investment portfolio details for Lyra Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lyra Therapeutics
Detailed financials for Lyra Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lyra Therapeutics Comparisons
Peer comparison for Lyra Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lyra Therapeutics
Lyra Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Decibel Therapeutics, TriSalus Life Sciences, Credence MedSystems and Akouos, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Medicines are developed to protect, repair, and restore hearing capacity.
|
|
| Locked | Locked | Locked |
Developer of drug delivery devices to treat cancers
|
|
| Locked | Locked | Locked |
Developer of smart devices for drug delivery
|
|
| Locked | Locked | Locked |
Developer of gene therapies to restore and preserve hearing capabilities in genetically defined populations
|
Detailed competitors of Lyra Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lyra Therapeutics
Complete news archive for Lyra Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lyra Therapeutics
Lyra Therapeutics was founded in 2005 and raised its 1st funding round 6 years after it was founded.
Lyra Therapeutics is headquartered in Watertown, United States.
Maria Palasis is the current CEO of Lyra Therapeutics.
Lyra Therapeutics is a funded company, having raised a total of $127.61M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lyra Therapeutics is 30.
Annual revenue of Lyra Therapeutics is $1.53M as on Dec 31, 2024.
Lyra therapeutics is developing small molecule based therapeutics for ear, nose, and throat (ENT) diseases. The companys proprietary product platform is a transmucosal therapeutic system which comprises of drugs that target ear, nose, and throat diseases and administered through a polymeric matrix. The companys lead product candidate LYR-210 used against chronic rhinosinusitis is used to deliver a long-acting formulation of an approved steroid, mometasone furoate, deep into the sinonasal tissues. It has completed the Phase 1 clinical trials. It can be used in patients both with and without nasal polyps.
Lyra Therapeutics's top competitors include Insulet, Decibel Therapeutics and TriSalus Life Sciences.
Yes, Lyra Therapeutics is publicly traded on NASDAQ under the ticker symbol LYRA.
Lyra Therapeutics has 10 investors. Key investors include HHS, RA Capital, Perceptive Advisors, ArrowMark Partners, and Polaris Partners.
The ticker symbol of Lyra Therapeutics is LYRA on NASDAQ.